Literature DB >> 8298798

Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.

M Tschöpl1, R C Miller, J Pelton, J C Stoclet, B Bucher.   

Abstract

1. The increase in perfusion pressure induced by neuropeptide Y (NPY), peptide YY (PYY) and related peptides were compared in the perfused rat tail artery precontracted by a submaximal concentration (1 microM) of the vasoconstrictor, phenylephrine. 2. NPY, PYY, [Leu31,Pro34]NPY, [Glu16,Ser18,Ala22,Leu28,31]NPY (ESALL-NPY) and the centrally truncated and stabilized analogues [D-Cys5,8-aminooctanoic acid7-20, Cys24]-NPY (D-Cys5-NPY) and [D-Cys7, 8-aminooctanoic acid8-17,Cys20]-NPY (D-Cys7-NPY) produced a concentration-dependent enhancement of the vasoconstrictor response induced by 1 microM phenylephrine. PYY was two times more potent than NPY and [Leu31,Pro34]NPY while ESALL-NPY, D-Cys7-NPY and D-Cys5-NPY were approximately 3, 5 and 16 times less potent than NPY respectively. NPY, D-Cys5-NPY and D-Cys7-NPY gave similar maximal responses whereas those observed for PYY, [Leu31,Pro34]NPY and ESALL-NPY were much greater than that of NPY. 3. NPY 13-36 and [des-Ser3,Lys4,Cys2,8-aminooctanoic acid3-24, D-Cys27]-NPY ([es-Ser3,Lys4]Cys2-NPY) were practically inactive at concentrations up to 3 microM, whereas [des-Ser3,Lys4,D-Cys2,8-aminooctanoic acid3-24,Cys27]-NPY ([des-Ser3,Lys4]D-Cys2-NPY), which differs from [des-Ser3,Lys4]Cys2-NPY in the disulphide bridge (a D-Cys in position 2 for [des-Ser3,Lys4]D-Cys2-NPY instead of an L-CYs for [des-Ser3,Lys4]Cys2-NPY) was a weak agonist the maximal effect of which could not be ascertained. 4. The contractile effects of [des-Ser3,Lys4]D-Cys2-NPY were additive with those of NPY and [Leu31,Pro34]NPY demonstrating that it is not a partial agonist but may simply not interact competitively with the receptor binding site for NPY. NPY and PYY interacted in a manner expected of agonists competing for the same binding site.5. PYY, NPY and [Leu31,Pro34]NPY were equipotent in displacing the I125-labelled PYY from binding sites on membranes from Y1-receptor expressing SK-N-MC cells, while the centrally truncated analogues were much less potent. The rank order of potencies for displacement of the I125-PYY binding by these peptides in SK-N-MC cells correlated with their activity in enhancing the vasoconstrictor response of phenylephrine in the tail artery. For the [des-Ser3,Lys4]D-Cys2-NPY analogue, the displacement pattern was more complex in that the displacement analysis revealed the presence of two binding sites.6. In conclusion, these data provide no evidence for other than postjunctional Y1-receptors mediating the enhancement of the contractile response elicited by phenylephrine in the perfused rat tail artery. The effects of [des-Ser3,Lys4]D-Cys2-NPY indicate that the Y1-receptor may possess an allosteric binding site.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298798      PMCID: PMC2175818          DOI: 10.1111/j.1476-5381.1993.tb13927.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Direct evidence for concomitant release of noradrenaline, adenosine 5'-triphosphate and neuropeptide Y from sympathetic nerve supplying the guinea-pig vas deferens.

Authors:  L Kasakov; J Ellis; K Kirkpatrick; P Milner; G Burnstock
Journal:  J Auton Nerv Syst       Date:  1988-02

3.  Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture.

Authors:  J L Biedler; L Helson; B A Spengler
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

4.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

5.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.

Authors:  J M Lundberg; L Terenius; T Hökfelt; C R Martling; K Tatemoto; V Mutt; J Polak; S Bloom; M Goldstein
Journal:  Acta Physiol Scand       Date:  1982-12

6.  Plasma concentration and vascular effect of beta-endorphin in spontaneously hypertensive and Wistar Kyoto rats.

Authors:  B Bucher; R Bettermann; P Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

7.  Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides.

Authors:  C Wahlestedt; N Yanaihara; R Håkanson
Journal:  Regul Pept       Date:  1986-02

8.  Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion.

Authors:  K Tatemoto
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

9.  Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers.

Authors:  E Ekblad; L Edvinsson; C Wahlestedt; R Uddman; R Håkanson; F Sundler
Journal:  Regul Pept       Date:  1984-04

10.  Neuropeptide Y distribution in the rat brain.

Authors:  Y S Allen; T E Adrian; J M Allen; K Tatemoto; T J Crow; S R Bloom; J M Polak
Journal:  Science       Date:  1983-08-26       Impact factor: 47.728

View more
  3 in total

1.  Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction.

Authors:  H Chen; C Fetscher; R F Schäfers; G Wambach; T Philipp; M C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

2.  Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist, BIBP 3226.

Authors:  H Gicquiaux; M Tschöpl; H N Doods; B Bucher
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

3.  A study of NPY-mediated contractions of the porcine isolated ear artery.

Authors:  R E Roberts; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.